Diclofenac potassium sachet, cambia patent expiry?

Diclofenac potassium sachets are a convenient oral form of the NSAID diclofenac, designed for rapid absorption and typically used for short‑term relief of pain and inflammation (e.g., arthritis, dental pain, menstrual cramps). The “sachet” format contains a pre‑measured dose in a single-use packet that you can dissolve in a small amount of water or take as a ready‑to‑drink solution.

What is “Cambia”?

In many markets “Cambia” refers to a brand name that markets diclofenac potassium sachets (often in 1 mg mL⁻¹ concentration). It’s usually a product of a larger pharmaceutical company that holds a marketing authorization for that specific dosage form. The brand name may differ from country to country, but the active ingredient and therapeutic class remain the same.

Patent status & expiry

Key points

1. Patent vs. regulatory exclusivity – A patent expiry does not automatically mean the product can be sold generically. The brand holder often enjoys regulatory exclusivity (e.g., market approval, clinical data exclusivity) that can extend commercial protection for a few extra years.

2. Generic availability – Once the patent expires and regulatory exclusivity lapses, other manufacturers can file for generic approval. In practice, generic diclofenac potassium sachets have appeared in many markets already, especially in lower‑cost regions.

3. “Cambia” specific – If “Cambia” is a brand that launched after the original diclofenac patents expired, it may be protected under a new formulation or delivery method patent (e.g., the sachet format). That secondary patent might still be in force, even though the core diclofenac patents have lapsed.

Practical takeaway

• If you’re a patient or prescriber: Diclofenac potassium sachets are widely available, often in generic versions, and can be a cost‑effective choice. Always follow your prescribing information and consult a pharmacist or doctor if you have specific concerns.

• If you’re a pharmacist or healthcare professional: Check the local regulatory database for the exact status of the “Cambia” brand in your region. In most jurisdictions, the core diclofenac patents are long expired, but the sachet formulation or any proprietary delivery technology may still be protected.

• If you’re a pharma professional: The patent landscape for diclofenac potassium sachets is largely mature. Any new entrant would need to navigate residual exclusivities and ensure compliance with local drug‑approval regulations.

Bottom line

Diclofenac potassium sachets are a well‑established, inexpensive option for pain management. The core diclofenac patents have long expired in most markets, but specific brands like “Cambia” may still hold secondary patents on the sachet formulation or delivery system. If you need the exact expiry date for a particular jurisdiction, let me know the country and I can look up the latest data for you.